The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multidisciplinary-tailored digital solution to data capture in early phase clinical trials.
 
Donna M. Graham
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Gemma Wickert
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Aptus Clinical (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Leanna Goodwin
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline UK Ltd. (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Joanna Clarke
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst)
 
Carla Timmins
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Dilshad Chang
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Alison Walker
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Amanda Rees
Employment - Cancer Research UK
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carrick Pharm (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Steffan Stringer
Travel, Accommodations, Expenses - Janssen
 
Adam Theis
No Relationships to Disclose
 
Louise Carter
Consulting or Advisory Role - Athenex; Bicycle Therapeutics
Research Funding - Athenex (Inst); Bristol-Myers Squibb (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Athenex; BerGenBio; BerGenBio
 
Natalie Cook
Consulting or Advisory Role - Epigene Therapeutics; Tarveda Therapeutics
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Redx Pharma (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); Vertex (Inst)
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Janssen; Octimet; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio
 
Fiona C. Thistlethwaite
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Ipsen; Pfizer; Roche
Research Funding - AB Science (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); AVEO (Inst); Bayer (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Debiopharm Group (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Exelixis (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Jennifer Bradford
No Relationships to Disclose
 
Jennifer Royle
No Relationships to Disclose
 
Andrew M. Hughes
Leadership - PCI Biotech
Stock and Other Ownership Interests - AstraZeneca
Honoraria - AstraZeneca; Athenex; Athenex; Carrick Therapeutics; PCI Biotech; Roche/Genentech; Sarah Cannon Research Institute
Consulting or Advisory Role - AstraZeneca; Athenex; Carrick Therapeutics; PCI Biotech; Roche/Genentech; Sarah Cannon Research Institute
Research Funding - AstraZeneca